- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
A Brexit Boost for German Pharma?
Research conducted by CPhI Worldwide, drawing from the CPhI Annual Report, ranks Germany as Europe’s preeminent pharma industry.
According to the report’s Pharma Index, Germany finished ahead of its European rivals in API manufacturing, competitiveness, innovation, finished product manufacturing, and growth potential, thus “consolidating its status as an elite pharmaceutical market.”
One of the most notable trends, the report states, is the sudden rise in anticipated growth potential for Germany in 2019/2020, increasing by 11% from 2018. The research’s authors attribute the shifting European outlook over the last couple of years to wider macro changes, as well as the continued strength of European pharma. Germany is perceived to be reaping a “Brexit boost” in its medium-term growth potential – with an equal drop in the UK scores directly correlating to the increases seen in Germany’s.
The full CPhI Pharma Market Index will be available later in the year as part of the CPhI 2019 Industry Report. This year’s CPhI Worldwide event will be held at Messe Frankfurt, Germany, November 5-7, 2019.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
